Want to see LNSR full AI Analyst Report?
LNSR Stock Chart & Stats
$8.30
-$0.23(-4.11%)
At close: 4:00 PM EDT
$8.30
-$0.23(-4.11%)
Day’s Range― - ―
52-Week Range$4.95 - $12.94
Previous Close$5.37
Volume49.28K
Average Volume (3M)172.68K
Market Cap
$87.11M
Enterprise Value$134.08
Total Cash (Recent Filing)$13.56M
Total Debt (Recent Filing)$2.38M
Price to Earnings (P/E)5.6
Beta0.96
Next Earnings
Nov 05, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.27
Shares Outstanding12,285,865
10 Day Avg. Volume81,863
30 Day Avg. Volume172,682
Financial Highlights & Ratios
PEG Ratio-0.79
Price to Book (P/B)-5.34
Price to Sales (P/S)2.38
P/FCF Ratio-9.32
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$11.50Price Target Upside38.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.07
Revenue Forecast (FY)$61.30M
Bulls Say, Bears Say
Bulls Say
Recurring Revenue StrengthThe high and growing recurring-revenue mix makes LENSAR’s business less dependent on one-time system placements. Procedure fees, consumables, and related revenue from the installed base can improve revenue visibility and support more durable growth as utilization expands.
ALLY Installed-Base ExpansionExpansion of the ALLY installed base broadens the platform’s footprint and creates additional opportunities for recurring procedure-related revenue. A larger base can also reinforce clinical adoption, customer familiarity, and future placement momentum across ophthalmic surgery accounts.
Revenue And Market-Share GrowthDouble-digit revenue growth alongside higher U.S. procedure share indicates that LENSAR is gaining commercial traction rather than relying solely on industry demand. Sustained share gains can strengthen its competitive position and provide a foundation for future system and procedure growth.
Bears Say
Negative Cash GenerationPersistent negative operating and free cash flow weakens LENSAR’s ability to fund expansion internally, even when reported earnings improve. If cash burn continues, the company may have less flexibility to invest in commercial growth, support operations, or absorb execution setbacks.
Unproven Profitability QualityThe sharp reported earnings turnaround is not yet supported by a consistent operating-profit history. The disconnect between positive net income and negative EBIT raises questions about repeatability, making future profitability more dependent on sustained operating improvement than the latest headline result suggests.
International Distribution Re-engagementThe incomplete restoration of international distributor relationships can restrain overseas placements, utilization, and recurring revenue growth over the coming quarters. A prolonged re-engagement process may also increase dependence on U.S. execution while delaying recovery in the broader global installed base.
LENSAR News
LNSR FAQ
What was LENSAR’s price range in the past 12 months?
LENSAR lowest stock price was $4.95 and its highest was $12.94 in the past 12 months.
What is LENSAR’s market cap?
LENSAR’s market cap is $87.11M.
When is LENSAR’s upcoming earnings report date?
LENSAR’s upcoming earnings report date is Nov 05, 2026 which is in 47 days.
How were LENSAR’s earnings last quarter?
LENSAR released its earnings results on Aug 13, 2026. The company reported $0.1 earnings per share for the quarter, beating the consensus estimate of -$0.165 by $0.265.
Is LENSAR overvalued?
According to Wall Street analysts LENSAR’s price is currently Undervalued.
Does LENSAR pay dividends?
LENSAR does not currently pay dividends.
What is LENSAR’s EPS estimate?
LENSAR’s EPS estimate is -0.05.
How many shares outstanding does LENSAR have?
LENSAR has 12,285,865 shares outstanding.
What happened to LENSAR’s price movement after its last earnings report?
LENSAR reported an EPS of $0.1 in its last earnings report, beating expectations of -$0.165. Following the earnings report the stock price went up 31.479%.
Which hedge fund is a major shareholder of LENSAR?
Currently, no hedge funds are holding shares in LNSR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
LENSAR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.50 (38.55% Upside)
$11.50 (38.55% Upside)
Blogger Sentiment
Bullish
LNSR Sentiment 100%
Sector Average 62%
Sector Average 62%
Hedge Fund Trend
Increased
By 70.2K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.98%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-1.22%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
LENSAR
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.
LNSR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented clear operational and financial improvements: double‑digit revenue growth (18% total, 20% recurring), strong procedure growth (23% procedure revenue, 13% volume), expanding installed base and the best adjusted EBITDA to date. These positives are tempered by a lower cash balance, reliance on a $1.1M tariff refund that boosted gross margin, near-term seasonality, expected normalization of operating expenses as commercial investments resume, and some timing/pricing uncertainty around backlog and distributor re-engagement. On balance, the fundamental business momentum (recurring revenue mix, procedures, ALLY adoption and profitability improvement) outweighs the short-term risks and one-time items.View all LNSR earnings summariesLNSR Stock 12 Month Forecast
Average Price Target
$11.50
▲(38.55% Upside)
Technical Analysis
Ownership Overview
42.09% Insiders
7.83% Mutual Funds
21.81% Other Institutional Investors
24.57% Public Companies and
Individual Investors